NEW YORK, December 13, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced it commenced a study of BRAVYL in Amyoptrophic Lateral Sclerosis (ALS) patients.
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. ALS is part of a wider group of disorders known as motor neuron diseases. The estimated prevalence of ALS in the United States is 5 per 100,000, or approximately 30,000 Americans currently who have the disease.
The aim of the REAL Study (Rho-kinasE for Als Study) is to assess the preliminary safety, efficacy, of BRAVYL in patients with ALS. The open label study will enroll 20 patients at up to 10 sites. Subjects will be treated with BRAVYL for 6 months.
There is a large and convincing body of preclinical evidence of BRAVYL’s effect on ALS in animal models. Additionally, there is persuasive human data from a compassionate use study in Europe, where three ALS patients were dosed with an intravenous version of BRAVYL for a month. In all three patients, decline in function was attenuated during and one month after fasudil infusions, in one patient breathing capacity increased during treatment, and in one muscle strength increased during treatment.
ABOUT WOOLSEY PHARMACEUTICALS
New York-based Woolsey Pharmaceuticals is focused on the treatment of rare, neurodegenerative diseases. The company’s lead product is BRAVYL (oral fasudil).